Physician profile
Brett B Bender
NPI 1285752998
$13,870.77
in general payments reported to CMS, 2019-2025
47 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,927 · 2020: $457 · 2021: $1,551 · 2022: $2,141 · 2023: $2,882 · 2024: $2,552 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,794 · Education: $500 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,794.38 |
| Education | $500.36 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,851.62 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,514.77 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $1,185.68 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $772.05 | 2019-2025 | |
| Leo Pharma INC. | $746.82 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $645.29 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $585.68 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $560.01 | 2019-2025 | Cabtreo, Siliq, Arazlo |
| Pfizer INC. | $529.53 | 2019-2025 | |
| Avita Medical Americas, LLC | $500.00 | 2023 | Recell |
| Incyte Corporation | $419.45 | 2023-2025 | Opzelura |
| Genzyme Corporation | $407.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $401.29 | 2022-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.31 | 2023-2025 | Spevigo, Cyltezo |
| Dermavant Sciences, INC. | $358.09 | 2023-2024 | Vtama |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $349.75 | 2019-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $341.33 | 2021-2023 | |
| Lilly USA, LLC | $332.95 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $258.25 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $192.29 | 2023-2025 | Zoryve |
| Almirall LLC | $170.29 | 2019-2025 | Seysara, Klisyri |
| Genentech USA, INC. | $149.46 | 2021-2023 | Xolair, Erivedge |
| Sanofi-Aventis U.S. LLC | $139.99 | 2019-2024 | |
| Organon LLC | $126.59 | 2024-2025 | Hadlima, Vtama |
| Vyne Pharmaceuticals INC. | $123.23 | 2020-2021 | |
| Biofrontera INC. | $109.69 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $84.39 | 2019-2025 | Otezla, Otezla |
| Medtronic, INC. | $80.77 | 2023 | Closurefast |
| Fresenius Kabi USA, LLC | $70.06 | 2023 | Idacio |
| Dusa Pharmaceuticals, INC. | $62.94 | 2019 | |
| Kerecis Limited | $62.25 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Sandoz INC. | $44.92 | 2019 | |
| Prugen, INC. Pharmaceuticals | $37.00 | 2019-2020 | |
| Convatec INC. | $33.94 | 2025 | |
| Verrica Pharmaceuticals INC. | $31.67 | 2025 | Ycanth |
| Epi Health, LLC | $30.65 | 2019 | |
| Revance Therapeutics, INC. | $29.98 | 2024 | Daxxify |
| Organogenesis INC. | $21.32 | 2024 | |
| Botanix Sb INC | $19.63 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $16.13 | 2019 | |
| Dermira, INC. | $14.99 | 2019 | |
| Mimedx Group, INC. | $14.69 | 2024 | |
| Paratek Pharmaceuticals, INC. | $14.46 | 2022 | |
| Janssen Scientific Affairs, LLC | $14.31 | 2020 | |
| Melinta Therapeutics, LLC | $11.58 | 2019 | |
| Promius Pharma LLC | $11.37 | 2019 | |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.